A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada, Reiji Fukano, Tetsuya Mori, Michi Kamei, Fumiko Tanaka, Junichi Ueyama, Masahiro Sekimizu, Tomoo Osumi, Takeshi Mori, Yuhki Koga, Kentaro Ohki, Naoto Fujita, Tetsuo Mitsui, Akiko M. Saito, Hiroya Hashimoto, Ryoji Kobayashi

Research output: Contribution to journalArticlepeer-review

Abstract

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalActa medica Okayama
Volume74
Issue number1
DOIs
Publication statusPublished - Feb 1 2020

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children'. Together they form a unique fingerprint.

Cite this